BlueBrainBoost
freedom-pharmacy
Purchases through the above links give commission which helps fund this website
Recent literature: GLP-1 receptor agonist
Date Journal Article title
2019 Apr Reprod Biomed Online GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
2019 Jun Diabetes Ther Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
2019 Jun Diabetes Obes Metab Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
2019 Jun Ann Pharmacother The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.
2019 Jun Obes Surg Duodenal-Jejunal Bypass Maintains Gut Permeability by Suppressing Gut Inflammation.
2019 Jun Cells Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice.
2019 Lancet Diabetes Endocrinol Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
2019 Lancet Diabetes Endocrinol Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
2019 Jun Lancet Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
2019 Jun Lancet Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
2019 Jun Lancet Oral semaglutide versus cutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
2019 Jun Lancet Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
2019 Jun N Engl J Med Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
2019 J Inflamm (Lond) The GLP-1 agonist, liraglutide, ameliorates inflammation through the activation of the PKACREB pathway in a rat model of knee osteoarthritis.
2019 Jun J Pharmacol Exp Ther SCO-267, a GPR40 full agonist, improves glycemic and body weight control in rat models of diabetes and obesity.
2019 Jun Life Sci Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage.
2019 Jun Eur J Endocrinol Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.
2019 Apr Can J Diabetes Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials.
2019 Artif Cells Nanomed Biote... GLP-1 receptor agonist lixisenatide protects against high free fatty acids-induced oxidative stress and inflammatory response.
2019 Jun Chembiochem Impact of stitution registry on receptor-activation profiles of backbone-modified glucagon-like peptide-1 analogues.
2019 Jun Endocr Pract THE IMPACT OF GLP-1 RECEPTOR AGONISTS ON PATIENTS WITH DIABETES ON INSULIN THERAPY.
2019 May Med Lett Drugs Ther Insulins for type 2 diabetes.
2019 Jun J Diabetes Investig Dulaglutide-combined basal plus correction insulin therapy contributes to ideal glycemic control in noncritical hospitalized patients.
2019 Jun Diabetes Obes Metab Do GLP-1RA and SGLT-2i reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
2019 Jun Adv Ther The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
2019 Jun J Comp Eff Res Treatment patterns, glycemic control amp; bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients.
2019 Diabetol Metab Syndr Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease.
2019 Indian J Endocrinol Metab SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.
2019 May Medicina (Kaunas) GLP-1 Receptor Agonists and Kidney Protection.
2019 May J Biol Chem Correction: Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP.
2019 May Diabetes Obes Metab A randomized trial comparing the efficacy and safety of treating patients with very elevated hba1c levels with basal-bolus insulin or a glp-1 receptor agonist plus basal insulin: The simple study.
2019 Jan Pharmacoeconomic Review R...
2019 May J Endocrinol Exenatide mitigates inflammation and hypoxia along with improved angiogenesis in obese fat tissue.
2019 May Mov Disord The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration.
2019 May Cell Biol Int Hyperglycemia induces NF-κB activation and MCP-1 expression via downregulating GLP-1R expression in rat mesangial cells: inhibition by metformin.
2019 May Diabetes Ther Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom.
2019 Epilepsy Res The novel GLP-1GIP dual receptor agonist DA3-CH is neuroprotective in the pilocarpine-induced epileptogenesis rat model.
2019 May Neurogastroenterol Motil PI 3-kinase- and ERK-MAPK-dependent mechanisms underlie Glucagon-Like Peptide-1-mediated activation of Sprague Dawley colonic myenteric neurons.
2019 Diabetes Metab Syndr Obes Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date.
2019 Drugs R D Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK.
2019 Patient Prefer Adherence Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.
2019 May Diabetes Res Clin Pract Series: Implications of the recent CVOTs in type 2 diabetes: Impact on guidelines: The endocrinologist point of view.
2019 May Mol Imaging Biol Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys40(AhxHYNIC-[99mTc]EDDA)NH2]-Exendin-4 over Conventional Imaging Modalities for Localization of Insulinoma.
2019 May Diabetes Ther Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting.
2019 J Obes Metab Syndr The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
2019 May Drug Res (Stuttg) Pharmacokinetic Study of SKL-18287, a Novel Long-Acting Glucagon-Like Peptide-1 Receptor Agonist, in Rats, Monkeys and Mini-Pigs.
2019 Jun J Endocrinol Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
2019 Sep Behav Brain Res Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer's disease.
2019 May Diabetes Res Clin Pract Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.
2019 Apr Nan Fang Yi Ke Da Xue Xue... [Effect of glucagon-like peptide 1 receptor agonists on body fat redistribution and muscle mass in overweight and obese type 2 diabetic patients].
2019 May BMJ Open Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
2019 Apr J Vis Exp Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution.
2019 eNeuro Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs.
2019 Expert Rev Cardiovasc Ther Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
2019 Diabetes Ther Injectable Antihyperglycemics: A Systematic Review and Critical Analysis of the Literature on Adherence, Persistence, and Health Outcomes.
2019 May Diabetes Obes Metab Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
2019 May Diabetes Obes Metab Efficacy and safety of an expanded dulaglutide dose range: A phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin.
2019 Apr J Diabetes Investig Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
2019 Apr J Neuroendocrinol Interleukin-6 in the central amygdala is bioactive and co-localised with glucagon-like peptide-1 receptor.
2019 Diabetes Ther GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data.
2019 Front Endocrinol (Lausanne) Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart.
2019 Apr J Cachexia Sarcopenia Muscle Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy.
2019 Ann Transl Med Long-acting glucagon-like peptide-1 receptor agonist-status December 2018.
2019 Obes Sci Pract Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5).
2019 Jul Neuropharmacology Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1RAktGSK3β signaling.
2019 Diabetes Care Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).
2019 Diabetes Res Clin Pract Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
2019 Rev Med Liege [Basal insulin degludec (Tresiba®)].
2019 Chronic Dis Transl Med Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus.
2019 Am J Manag Care Authors' reply to "Comment on generalizability of GLP-1 RA CVOTs in US T2D population".
2019 Apr IUBMB Life The GLP1 Receptor Agonist Liraglutide Protects Against Oxidized LDL-Induced Endothelial Inflammation and Dysfunction via KLF2.
2019 Apr Gastroenterology Remission of bile acid malabsorption symptoms following treatment with the glucagon-like peptide 1 receptor agonist liraglutide.
2019 Clinicoecon Outcomes Res Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA.
2019 Apr J Clin Endocrinol Metab Effect of the GLP-1 receptor agonist exenatide on impaired awareness of hypoglycemia in type 1 diabetes; a randomized controlled trial.
2019 Apr J Neuroinflammation Highly glycosylated CD147 promotes hemorrhagic transformation after rt-PA treatment in diabetes: a novel therapeutic target?